Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00035932
Status:
COMPLETED
Last Update Posted:
2010-12-24
First Post:
2002-05-06
Brief Title:
Atazanavir BMS-232632 in Combination With Ritonavir or Saquinavir and LopinavirRitonavir Each With Tenofovir and a Nucleoside in Subjects With HIV
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
Phase III Open Label Atazanavir BMS-232632 in Combination With Ritonavir or Saquinavir and LopinavirRitonavir Each With Tenofovir and a Nucleoside in Subjects With HIV
Status:
COMPLETED
Status Verified Date:
2010-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to learn how well atazanavir ATV works in combination with ritonavir RTV or saquinavir SQV with tenofovir TDF and a nucleoside to reduce the viral load of treatment experienced subjects with human immunodeficiency virus HIV There is a comparison arm with lopinavir LPVRTV and TDF and a nucleoside
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None